A Phase 3 interventional study of ARICEPT in Dementia With Parkinson's Disease, sponsored by Eisai Limited. Completed at 4 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-05-10.
Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing donepezil in Dementia — none open to participants now, none under way, none of them phase 3. Donepezil · Dementia.
Among the 26 studies testing donepezil in Dementia, this one is one of 2 that started in 2002, is one of 8 in phase 3, and was the 7th registered.
2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →None of the 26 studies testing donepezil in Dementia is open now. The open studies under Dementia, anywhere →
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.
This study: 40 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 151 across the 24 interventional studies. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Limited, one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Limited is the lead sponsor of 48 studies on the registry; 2 are open to participants now.
15 studies in Dementia by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 15 finished, 6 (40%) have results posted.
Among the 15 studies in Dementia by Eisai Co., Ltd., this one is the only one that started in 2002, is one of 7 in phase 3, and was the 3rd registered.
Eisai Co., Ltd.’s Dementia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing donepezil in Dementia, from their registry updates:
Among Eisai Co., Ltd.’s 15 in Dementia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.
Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.
Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.
PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.
The record gives a start of Aug 2002 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil